Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glioblastoma Multiforme

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    115 result(s) found for: Glioblastoma Multiforme. Displaying page 3 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2018-000046-19 Sponsor Protocol Number: 64616 Start Date*: 2018-11-26
    Sponsor Name:Radboud University Medical Center
    Full Title: 18F-PSMA PET/CT for visualization of glioblastoma multiforme
    Medical condition: Patients with suspected/detected GBM on T1w-Gd-MRI
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006153 Brain tumor LLT
    20.0 100000004865 10053764 Brain tumor operation LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003045-42 Sponsor Protocol Number: CV-005 Start Date*: 2014-03-24
    Sponsor Name:CytoVac A/S
    Full Title: An Open-labelled, Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients with Glioblastoma Multiform...
    Medical condition: The overall purpose of the study is to investigate the efficacy and safety of ALECSAT in GBM patients either with relapse of GBM after first line treatments (followed by reoperation if possible). T...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001363-46 Sponsor Protocol Number: ML25739 Start Date*: 2011-08-22
    Sponsor Name:ROCHE
    Full Title: RANDOMIZED, NON COMPARATIVE PHASE II TRIAL WITH BEVACIZUMAB AND FOTEMUSTINE IN THE TREATMENT OF RECURRENT GLIOBLASTOMA.
    Medical condition: Glioblastoma multiforme progressed after a first line treatment with temozolomide and radiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002685-23 Sponsor Protocol Number: ICT-107-301 Start Date*: 2016-08-19
    Sponsor Name:ImmunoCellular Therapeutics, Ltd.
    Full Title: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy.
    Medical condition: Treatment of newly diagnosed glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000410-38 Sponsor Protocol Number: StrateGlio-1802 Start Date*: 2018-10-17
    Sponsor Name:Centre Oscar Lambret
    Full Title: Phase III randomised trial evaluating treatment intensification with temozolomide in adults with a glioblastoma
    Medical condition: Adults with a de novo glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005177-29 Sponsor Protocol Number: EORTC 26052-22053 Start Date*: 2006-11-10
    Sponsor Name:EORTC
    Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma
    Medical condition: Patients with Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-004968-41 Sponsor Protocol Number: CPRC 2007-Dr BEAUCHESNE-TEMOFRAC Start Date*: 2008-02-06
    Sponsor Name:CHU DE NANCY - DIRECTION DE LA RECHERCHE CLINIQUE ET DE L'INNOVATION
    Full Title: Essai de phase II testant une association concomitante irradiation cérébrale ultra-fractionnée – témozolomide pour des glioblastomes multiformes inopérables de novo
    Medical condition: Glioblastomes multiformes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002775-28 Sponsor Protocol Number: GBM - ANOCEF01 Start Date*: 2008-10-06
    Sponsor Name:Centre Georges François Leclerc
    Full Title: Evaluation de l'association irinotécan/bévacizumab utilisée en néo-adjuvant et en adjuvant d'une radiochimiothérapie avec témozolomide concomitant pour les glioblastomes non résécables. Etude de ph...
    Medical condition: GLIOBLASTOMES MULTIFORME (GBM) NON RESECABLES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001533-17 Sponsor Protocol Number: EORTC26053-22054 Start Date*: 2007-06-25
    Sponsor Name:EORTC European Organisation for research and treatment of cancer
    Full Title: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.
    Medical condition: anaplastic glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004015-31 Sponsor Protocol Number: WPD-201 Start Date*: 2021-09-10
    Sponsor Name:WPD Pharmaceuticals Sp. z o.o.
    Full Title: A Multicenter, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failur...
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003659-40 Sponsor Protocol Number: CNS-201 Start Date*: 2022-01-03
    Sponsor Name:CNS Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multifor...
    Medical condition: Glioblastoma Multiforme (WHO Grade IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003129-27 Sponsor Protocol Number: CBKM120E2102 Start Date*: 2014-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)
    Medical condition: recurrent glioblastoma multiform
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003193-10 Sponsor Protocol Number: CDKO-125a-002 Start Date*: 2009-02-24
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma
    Medical condition: Phase I Part: Recurrent Malignant Glioma Phase II Part: Recurrent Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065443 Malignant glioma LLT
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003089-38 Sponsor Protocol Number: FG001-CT-001 Start Date*: 2020-09-03
    Sponsor Name:FluoGuide A/S
    Full Title: An open-label, dose escalation, single-dose administration, multi-center phase I/II trial of FG001 (an imaging agent), in patients with glioblastoma scheduled for neurosurgery
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022160-13 Sponsor Protocol Number: H9H-MC-JBAI Start Date*: 2011-02-21
    Sponsor Name:Eli Lilly and Company
    Full Title: Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma
    Medical condition: Glioblastoma Multiforme (GBM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013406-13 Sponsor Protocol Number: GBM-DC-2009 Start Date*: 2009-10-07
    Sponsor Name:Masaryk University
    Full Title: First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study...
    Medical condition: Glioblastoma Multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003101-85 Sponsor Protocol Number: OSAG 101-BSA-05 Start Date*: 2007-05-14
    Sponsor Name:Oncoscience AG
    Full Title: Phase-III study of standard radiotherapy plus concomitant and adjuvant OSAG 101 (Theraloc®) plus Temozolomide vs. standard radiotherapy plus concomitant and adjuvant Temozolomide in patient with ne...
    Medical condition: Glioblastoma multiforme grade IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003911-63 Sponsor Protocol Number: GERT Start Date*: 2006-01-12
    Sponsor Name:University of Heidelberg, Frau I. Gürkan, Kaufmännische Direktorin
    Full Title: Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial
    Medical condition: Glioblastoma Multiforme (GBM)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003668-30 Sponsor Protocol Number: KCP-330-004 Start Date*: 2013-11-12
    Sponsor Name:Karyopharm Therapeutic, Inc.
    Full Title: A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent Gliomas
    Medical condition: Recurrent glioblastoma or other brain cancer after failure of radiation therapy and temozolomide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073128 Anaplastic oligodendroglioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027769 Mixed oligo-astrocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026659 Malignant oligodendroglioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004214-14 Sponsor Protocol Number: P311-201 Start Date*: 2016-10-13
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts f...
    Medical condition: Advanced Solid Tumors/Relapsed/Recurrent Glioblastoma Multiforme (GBM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 01:04:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA